Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewLY 2109761 is a selective dual TGF-β receptor type I and II (TβRI/II) inhibitor (Ki values are 38 and 300 nM in a cell-free assay, respectively); it inhibits the kinase activity of both TGF-βRI and TGF-βRII. In vitro, it significantly inhibits the growth, motility, and invasiveness of L3.6pl/GLT pancreatic cancer cells and completely suppresses TGF-β-induced Smad2 phosphorylation. In vivo, LY 2109761, in combination with Gemcitabine, significantly reduces tumor volume and spontaneous abdominal metastases in a murine model of metastatic pancreatic cancer. LY 2109761 is orally bioavailable.
分子量 | 441.53 |
公式 | C26H27N5O2 |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 700874-71-1 |
PubChem ID | 11655119 |
InChI Key | IHLVSLOZUHKNMQ-UHFFFAOYSA-N |
Smiles | N1=CC=CC=C1C2=NN3C(=C2C=4C=CN=C5C=C(OCCN6CCOCC6)C=CC54)CCC3 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 8.83 | 20 温和加热 | |
ethanol | 8.83 | 20 温和加热 |
以下数据基于产品分子量 441.53。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.2 mM | 11.32 mL | 56.62 mL | 113.24 mL |
1 mM | 2.26 mL | 11.32 mL | 22.65 mL |
2 mM | 1.13 mL | 5.66 mL | 11.32 mL |
10 mM | 0.23 mL | 1.13 mL | 2.26 mL |
参考文献是支持产品生物活性的出版物。
Melisi et al (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol.Cancer Ther. 7 829 PMID: 18413796
If you know of a relevant reference for LY 2109761, please let us know.
关键词: LY 2109761, LY 2109761 supplier, LY2109761, selective, inhibitors, inhibits, TGF-βRI, TGF-βRII, TGF-β, TGF-betaRI, TGF-betaRII, TGFbRI, TGFbRII, TGFbR1, TGFbR2, tgf-b1, tgf-b2, transforming, growth, factors, beta, receptors, TGF-beta, in, vivo, orally, bioavailable, pancreatic, cancer, meta, Receptors, 7864, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。
目前没有 LY 2109761 的引用文献。 您是否知道使用了 Tocris LY 2109761 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review LY 2109761 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.